Evidence map›Paper›PMID 37927587›Full record

ArticleFrontiers in pharmacology2023

Advancing pharmacogenetic testing in a tertiary hospital: a retrospective analysis after 10 years of activity.

Stefan Stewart, Jose Manuel Dodero-Anillo, Javier Guijarro-Eguinoa, Pedro Arias, Arturo Gómez López De Las Huertas, Enrique Seco-Meseguer, Irene García-García, Elena Ramírez García, Carlos Rodríguez-Antolín, Antonio J Carcas and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Frontiers in pharmacology · 2025
    Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Stefan StewartClinical Pharmacology Department, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Jose Manuel Dodero-AnilloClinical Pharmacology, Hospital Universitario Puerto Real, Cadiz, Spain.
Javier Guijarro-EguinoaClinical Pharmacology Department, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Pedro AriasPharmacogenetics Laboratory, Genetics Department, La Paz University Hospital, Madrid, Spain.
Arturo Gómez López De Las HuertasClinical Pharmacology Department, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Enrique Seco-MeseguerClinical Pharmacology Department, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Irene García-GarcíaClinical Pharmacology Department, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Elena Ramírez GarcíaClinical Pharmacology Department, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Carlos Rodríguez-AntolínExperimental Therapies and Novel Biomarkers in Cancer, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain.
Antonio J CarcasClinical Pharmacology Department, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Sonia Rodriguez-NovoaGenetics of Metabolic Diseases Laboratory, Genetics Department, La Paz University Hospital, Madrid, Spain.
Rocio Rosas-AlonsoPharmacogenetics Laboratory, Genetics Department, La Paz University Hospital, Madrid, Spain.
Alberto M BorobiaClinical Pharmacology Department, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Universidad Autónoma de Madrid · ESHospital La Paz Institute for Health Research · ESHospital Universitario La Paz · ESHospital Universitario Puerto Real · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The field of pharmacogenetics (PGx) holds great promise in advancing personalized medicine by adapting treatments based on individual genetic profiles. Despite its benefits, there are still economic, ethical and institutional barriers that hinder its implementation in our healthcare environment. A retrospective analysis approach of anonymized data sourced from electronic health records was performed, encompassing a diverse patient population and evaluating key parameters such as prescribing patterns and test results, to assess the impact of pharmacogenetic testing. A head-to-head comparison with previously published activity results within the same pharmacogenetic laboratory was also conducted to contrast the progress made after 10 years. The analysis revealed significant utilization of pharmacogenetic testing in daily clinical practice, with 1,145 pharmacogenetic tests performed over a 1-year period and showing a 35% growth rate increase over time. Of the 17 different medical departments that sought PGx tests, the Oncology department accounted for the highest number, representing 58.47% of all genotyped patients. A total of 1,000 PGx tests were requested for individuals susceptible to receive a dose modification based on genotype, and 76 individuals received a genotype-guided dose adjustment. This study presents a comprehensive descriptive analysis of real-world data obtained from a public tertiary hospital laboratory specialized in pharmacogenetic testing, and presents data that strongly endorse the integration of pharmacogenetic testing into everyday clinical practice.

Indexed as

personalized medicinepharmacogenetic dosingpreemptive genotypingreal-world dataretrospective analysis

Identifiers

PMID37927587
PMCPMC10622662
OpenAlexW4387776723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.